Study Shows Real-World Outcomes of First-Line Palbociclib Plus Fulvestrant in HR+, HER2– Metastatic Breast Cancer
Palbociclib (Ibrance; Pfizer) plus fulvestrant (Faslodex; AstraZeneca) as a first-line treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2–) metastatic breast cancer (MBC) demonstrated favorable real- …